Cargando…
New therapies in multiple myeloma
The melphalan-prednisone regimen has been considered as standard therapy for patients with multiple myeloma (MM) for many years. Recently, high-dose chemotherapy with stem-cell support has extended progression-free survival and increased overall survival, and it is now considered conventional therap...
Autores principales: | Merchionne, F., Perosa, F., Dammacco, F. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779346/ https://www.ncbi.nlm.nih.gov/pubmed/17972050 http://dx.doi.org/10.1007/s10238-007-0134-y |
Ejemplares similares
-
u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progression
por: Ciavarella, S, et al.
Publicado: (2017) -
Proteolytic Activity of Human Lymphoid Tumor Cells.
Correlation with Tumor Progression
por: Vacca, Angelo, et al.
Publicado: (2000) -
Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update
por: Ria, Roberto, et al.
Publicado: (2018) -
Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma
por: Ribatti, D, et al.
Publicado: (1999) -
Posttransplant maintenance therapy in multiple myeloma: the changing landscape
por: Sengsayadeth, S, et al.
Publicado: (2017)